Shimadzu Europe
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

Jurgen Semmer - new MD Shimadzu Europa

Jürgen Semmler appointed as new managing director at Shimadzu Europa

, 19 July 2021/in E-News /by panglobal
Jurgen Semmer - new MD Shimadzu Europa

Jürgen Semmler

Shimadzu, one of the world leaders in analytical instrumentation, has appointed Jürgen Semmler as the new managing director of its European organization from July 1, 2021. Previously, head of Shimadzu Deutschland, he succeeds Jürgen Kwass, who led Shimadzu Europa from 2003 to the present and is now retiring. Semmler and Kwass have both been affiliated with Shimadzu for a long time and joined the company in the second half of the 1980s.

Jürgen Semmler graduated in chemical engineering at Essen University, Germany, before joining Shimadzu in 1987 as an HPLC service engineer. He gained international experience as a European team member in the development of a global software and since 1996 as manager of the European Customer Support Center. In 2006, he was then appointed Managing Director of newly founded Shimadzu Deutschland. Under his management, the company has grown from 60 to more than 150 employees, and its sales from €19 million to over €40 million. Previously independent companies were incorporated into the organization as technical offices under the overall management of Shimadzu Deutschland.

Thanks to Jürgen Kwass

As Shimadzu Europa and Shimadzu Deutschland are both based in Duisburg, Germany, the two Managing Directors have always worked closely together.

Semmler commented: “Under Jürgen Kwass’ aegis, Shimadzu’s network was rolled out to every European country and set up structurally and in terms of staff to serve the customer needs of medium-sized companies as well as global players. Shimadzu’s growth is closely linked to his commitment and name.”

Shimadzu Europa has been active on the continent since 1968. Its medical and laboratory solutions are used in health care, the latter primarily in science and technology, particularly in almost every manufacturing industry such as chemicals, pharmaceuticals and biotechnology, food and beverage, advanced manufacturing, automotive, semiconductors and plastics. They serve consumer, patient and environmental protection as well as process and quality control.

Future development and growth trends

With regard to technical trends, such as automation, miniaturization of systems, digitization and hyphenated techniques, ABC has provided significant impetus to the market and initiated developments in recent years.

Semmler noted: “Digitization in particular holds both technological and creative potential. In analytical instrumentation and medical technology, it facilitates seamless workflows as well as simpler, more accurate and faster measurements and tests. It also enables analytics and medical technology to merge to deliver solutions for the most challenging medical conditions, such as the diagnosis and treatment of cancer or dementia.”

Shimadzu Europa is Shimadzu’s oldest continental foreign organization and plays an important role in the company’s growth and globalization process.

Semmler said: “In addition to our technological expertise, we also want to continue to strengthen our presence and network on an organizational level throughout the European region, expand our teams, and increase sales and market share. I am looking forward to the tasks ahead.”

https://clinlabint.com/wp-content/uploads/sites/2/2021/07/Jurgen-Semmler_web.jpg 1761 1452 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-07-19 10:59:072021-07-19 10:59:07Jürgen Semmler appointed as new managing director at Shimadzu Europa
dna sequence

Discovery shows human cells can write RNA sequences into DNA

, 7 July 2021/in E-News /by panglobal

Cells contain machinery that duplicates DNA into a new set that goes into a newly formed cell. That same class of machines, called polymerases, also build RNA messages, which are like notes copied from the central DNA repository of recipes, so they can be read more efficiently into proteins.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/07/dna_sequence.jpg 1426 2048 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-07-07 15:07:432021-07-07 15:07:43Discovery shows human cells can write RNA sequences into DNA
research accelerator

SARS-CoV-2 research accelerator: Worldwide network headed by Goethe University develops protocols for labs

, 7 July 2021/in E-News /by panglobal

For the development of drugs or vaccines against COVID-19, research needs virus proteins of high purity. For most of the SARS-CoV-2 proteins, scientists at Goethe University Frankfurt and a total of 36 partner laboratories have now developed protocols that enable the production of several milligrams of each of these proteins with high purity, and allow […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/07/research_accelerator-scaled.jpg 1953 2560 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-07-07 15:04:512021-07-07 15:04:51SARS-CoV-2 research accelerator: Worldwide network headed by Goethe University develops protocols for labs
Kidney Cross Section

Phase II study shows promising results for targeted treatment for IgA nephropathy

, 7 July 2021/in E-News /by panglobal

Due to the immunological pathogenesis of IgA nephropathy (IgAN), patients used to be given immunosuppressive therapy; however, this was shown to have no long-term benefit over optimal supportive therapy.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/07/Kidney_Cross_Section.png 281 211 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-07-07 15:02:302021-07-07 15:10:01Phase II study shows promising results for targeted treatment for IgA nephropathy
glia cell

New glial cells discovered in the brain: Implications for brain repair

, 7 July 2021/in E-News /by panglobal

Neurons, nerve cells in the brain, are central players in brain function. However, a key role for glia, long considered support cells, is emerging. A research group at the University of Basel has now discovered two new types of glial cells in the brain, by unleashing adult stem cells from their quiescent state. These new […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/07/glia_cell.jpg 566 1134 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-07-07 14:59:362021-07-07 14:59:36New glial cells discovered in the brain: Implications for brain repair
alzheimers

FDA approves aducanumab for treatment of Alzheimer’s

, 7 July 2021/in E-News /by panglobal

The U.S. FDA has approved Aduhelm (aducanumab) developed by Biogen, Cambridge, Massachusetts, for the treatment of Alzheimer’s. Aduhelm was approved using the ‘accelerated approval pathway’.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/07/alzheimers.png 1080 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-07-07 14:49:512021-07-07 14:54:25FDA approves aducanumab for treatment of Alzheimer’s
Dr Nick Roesen

Native Antigen Company wins ‘The Best COVID-19 Responder’ at OBN 2020 Awards

, 7 July 2021/in E-News /by panglobal

The Native Antigen Company, part of LGC Clinical Diagnostics and one of the world’s leading suppliers of reagents that enables research into diagnostics and vaccines for emerging and endemic infectious diseases, won ‘The Best COVID-19 Responder’ at the OBN 2020 Awards. The award recognises the company’s outstanding contribution to the fight against COVID-19.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/07/Dr-Nick-Roesen.jpg 1058 1282 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-07-07 14:44:412021-07-07 14:44:41Native Antigen Company wins ‘The Best COVID-19 Responder’ at OBN 2020 Awards
transgene biotek

Transgene strengthen global IP protection for its novel Invir.IO oncolytic viruses encoding ICIs

, 7 July 2021/in E-News /by panglobal

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, has received a patent from the Japan Patent Office for their oncolytic virus (OV) backbone VVcopTK-RR- that encodes one or more immune checkpoint inhibitors (ICIs).

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/07/transgene_biotek.jpg 304 600 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-07-07 14:42:112021-07-07 15:10:56Transgene strengthen global IP protection for its novel Invir.IO oncolytic viruses encoding ICIs
Lunaphore Matthias Weber

Lunaphore appoints Matthias Weber, former President of Leica Biosystems, to Board of Directors

, 7 July 2021/in E-News /by panglobal

Lunaphore Technologies, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, has appointed Matthias Weber, former President of Leica Biosystems, to its Board of Directors. Weber has been appointed to represent the interests of strategic investor PHC Holdings Corporation (PHCHD), who previously invested in Lunaphore through a Series C financing round in 2020.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/07/Lunaphore_Matthias-Weber.png 560 450 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-07-07 14:38:372021-07-07 14:38:37Lunaphore appoints Matthias Weber, former President of Leica Biosystems, to Board of Directors
iksuda therapeutics

Iksuda Therapeutics closes $47 million financing round

, 7 July 2021/in E-News /by panglobal

Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, has completed a US$47 million financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/07/iksuda-therapeutics.jpg 256 384 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-07-07 14:36:122021-07-07 14:36:12Iksuda Therapeutics closes $47 million financing round
Page 66 of 227«‹6465666768›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

November 2025

CLi Cover nov 2025
13 November 2025

New Chromsystems Product for Antiepileptic Drugs Testing

11 November 2025

Trusted analytical solutions for reliable results

10 November 2025

Chromsystems | Therapeutic Drug Monitoring by LC-MS/MS

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription